Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma

Melanoma (Skin) Clinical Trial

Official title:

Studies of Familial Melanoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00450593
• Other study ID #: CRUK-LCC-99/3/45
• Secondary ID: CDR0000532941EU-
• Status: Recruiting
• Phase: N/A
• First received: March 20, 2007
• Last updated: August 9, 2013
• Start date: January 1989

Study information

• Verified date: April 2008
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: Unspecified
• Study type: Observational

Clinical Trial Summary

RATIONALE: Identifying gene mutations and other risk factors in patients with melanoma and in families with a history of hereditary melanoma may help doctors identify persons at risk for melanoma and other types of cancer. It may also help the study of cancer in the future.

PURPOSE: This clinical trial is studying gene mutations in patients with melanoma and in families with a history of hereditary melanoma.

Description:

OBJECTIVES:

• Determine the incidence and etiologic significance of variants of known melanoma susceptibility genes (MSGs) in families with multiple cases of melanoma.

• Determine the proportion of multiple-case families that are explained by high-penetrance mutations in known MSGs.

• Determine the proportion of multiple-case families that are explained by these mutations and whether it varies with latitude, as a surrogate for ultraviolet exposure, with number of affected relatives, with average age at onset of melanoma in relatives, with presence of multiple primary melanoma, or with other family-specific variables.

• Determine the penetrance of MSG mutations in these families.

• Determine if the penetrance varies with age, sex, or birth cohort.

• Determine if the penetrance varies with the gene involved or nature of the mutation.

• Assess the penetrance in mutations that also have a deleterious effect on the alternative splice product, p14ARF.

• Determine whether carriers of MSGs have an increased susceptibility to other types of cancer.

• Determine the risk of other types of cancers for mutation carriers.

• Determine environmental exposures, in particular sun exposure, that modify risk of melanoma in MSG mutation carriers.

• Determine the cutaneous phenotypes that correlate with melanoma risk in these families.

• Correlate cutaneous phenotypes with the presence of MSG variants.

• Determine the effect of other covariates, such as sun exposure or the presence of alleles of putative modifying genes (e.g., MC1R or CDKN2A), on phenotype.

• Determine if modifier genes, such as those controlling pigmentation of the skin, and therefore sun susceptibility, modify risk in MSG mutation carriers.

• Identify any histopathological correlates of MSG status in primary tumors arising in melanoma-susceptible individuals in these families.

• Identify any histopathological correlates of primary melanomas in carriers of MSG mutations with other covariates.

OUTLINE: This is a case-control, multicenter study.

Participants complete 2 questionnaires and assist in the creation and expansion of a family pedigree. Blood samples are examined for melanoma susceptibility gene mutations, including CDK4 and CDKN2A.

Participants are also examined for moles and photographed. Physical variables (e.g., skin, eye, and hair pigmentation) and sun damage (solar lentigines and freckling) are also noted.

If available, tissue samples are examined for Clark level, Breslow thickness, and frequency of mitoses. Peri-lesional skin from tumors is examined by p53 staining.

Participants are followed periodically to monitor cancer development.

Peer reviewed and funded or endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 5,000 participants will be accrued for this study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

DISEASE CHARACTERISTICS:

• Meets one of the following criteria:

• Prior multiple primary melanomas

• Histological samples available

• Family history of melanoma, with melanoma in two first-degree relatives (e.g., cases of melanoma in both a mother and son or in two brothers but not in two cousins)

• Family history of melanoma, where three or more individuals (of any relationship) have had melanoma

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified

Study Design

N/A

Related Conditions & MeSH terms

• Hereditary Multiple Melanoma
• Melanoma
• Melanoma (Skin)

Intervention

Genetic:
• gene expression analysis

• microarray analysis

• molecular genetic technique

• mutation analysis

Other:
• laboratory biomarker analysis

Procedure:
• mutation carrier screening

• study of high risk factors

Locations

Country	Name	City	State
United Kingdom	Leeds Cancer Centre at St. James's University Hospital	Leeds	England

Sponsors (1)

Lead Sponsor	Collaborator
Leeds Cancer Centre at St. James's University Hospital

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Predictive significance of melanoma susceptibility gene (MSG) mutations in the CDKN2A gene			No
Primary	Susceptibility to other types of cancer as a feature of MSG mutations			No
Primary	Risk of other types of cancers in mutation carriers			No
Primary	Environmental exposures, in particular sun exposure, that modify risk of melanoma in MSG mutation carriers			No